TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) Operating income 2016–2025
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) annual operating income history from SEC filings — each fiscal year as reported.
-$125.7MFY2025 · since FY2016: -$39.0M → -$125.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$125.7M | +8.0% |
| FY2024 | -$136.7M | -15.5% |
| FY2023 | -$118.4M | -5.6% |
| FY2022 | -$112.1M | -21.4% |
| FY2021 | -$92.3M | -82.8% |
| FY2020 | -$50.5M | -75.2% |
| FY2019 | -$28.8M | -9.5% |
| FY2018 | -$26.3M | -23.6% |
| FY2017 | -$21.3M | +45.4% |
| FY2016 | -$39.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TNXP financial trends
TNXP RevenueTNXP Net incomeTNXP Net marginTNXP Gross profitTNXP Gross marginTNXP Operating marginTNXP Operating cash flowTNXP Free cash flowTNXP Capital expendituresTNXP Return on equityTNXP Stock buybacksTNXP Dividends paidTNXP Total assetsTNXP Total liabilitiesTNXP Shareholders’ equityTNXP overview →